Clinical recovery time for Sars-Cov-2 Infection in healthcare workers with full and booster vaccination
Abstract
The increase of infections at the end of 2021 and January 2022 due to the Omicron variant in Ecuador, raises doubts regarding the effectiveness of booster vaccination, which questions the protection provided by booster vaccination and how often to apply it. A sample of 419 cases is taken and compared with the personnel that have complete (58% with third dose) and incomplete (42%) immunization schedules as of December 2021 and January 2022, and the time of symptomatic recovery after SARS infection is determined afterwards. The results show no difference in the recovery time in patients within the two groups and similar symptoms were observed. It is concluded that, given the results, there is no evidence of the need for a third dose in general, but rather, it would be reasonable to focus the efforts of a second booster only in specific vulnerable populations, thus avoiding unnecessary adverse effects that are becoming more frequent, and even allowing the existing vaccines available in countries where they are really needed.Downloads
References
PAHO/WHO | Pan American Health Organization/World Health Organization. COVID-19 Situation Reports. Disponible en https://www.paho.org/en/covid-19-situation-reports
Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir Med. 2021; 9(12):1450–1466. https://doi.org/10.1016/S2213-2600(21)00407-0.
Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe. 2021; 2(12): e666–e675. https://doi.org/10.1016/S2666-5247(21)00219-6.
Bhattacharya A, Ranjan P, Ghosh T, Agarwal H, Seth S, Maher GT, et al. Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: A single centre, cross-sectional analytical study from India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021; 15(5):102238. https://doi.org/10.1016/j.dsx.2021.102238.
Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, Ward T. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir Med. 2021; 9(12):1450-1466. doi: 10.1016/S2213-2600(21)00407-0.
Alba JMG, Pérez-Martínez Z, Boga JA, Rojo-Alba S, de Oña JG, Alvarez-Argüelles ME, et al. Emergence of new SARS-CoV2 Omicron variants after the change of surveillance and control strategy. Microorganisms. 2022; 10(10):1954. http://dx.doi.org/10.3390/microorganisms10101954
Cirillo N. Do health-care workers need a COVID-19 vaccine booster? Lancet Infect Dis. 2022; 22:20. https://doi.org/10.1016/S1473-3099(21)00782-9.
Alcívar Zambrano D, Espinoza Centeno A, Escobar Segovia KF. Impacto de la pandemia por SARS-CoV-2 en los trabajadores de un Hospital de Guayaquil en el año 2020. Rev San Gregor. 2022; 1:63–73. https://doi.org/10.36097/rsan.v0i49.1958
GISAID. Tracking of hCoV-19 Variants. Global Initiative on Sharing All Influenza Data. Disponible en: https://gisaid.org/hcov19-variants/
Al-Naamani K, Al-Jahdhami I, Al-Tamtami W, Al-Amri K, Al-Khabori M, Sinani SA, et al. Prevalence and persistence of SARS-CoV2 antibodies among healthcare workers in Oman. Journal of Infectionand Public Health. 2021; 14(11):1578–1584. https://doi.org/10.1016/j.jiph.2021.09.006
Chau NVV, Ngoc NM, Nguyet LA, Quang VM, Ny NTH, Khoa DB, et al. An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine 2021; 41:101143. https://doi.org/10.1016/j.eclinm.2021.101143
Copyright (c) 2023 FACSALUD-UNEMI
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los artículos de la Revista FACSalud UNEMI son difundidos bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Los autores mantienen los derechos de autor, y, por lo tanto, son libres de compartir, copiar, distribuir, ejecutar y comunicar públicamente la obra bajo las condiciones siguientes: Reconocer los créditos de la obra especificada por el autor e indicar si se realizaron cambios (puede hacerlo de cualquier forma razonable, pero no de una manera que sugiera que el autor respalda el uso que hace de su obra. No utilizar la obra para fines comerciales. En caso de remezcla, transformación o desarrollo, no puede distribuirse el material modificado.
